Skip to content

A multicenter prospective clinical study of endoscopic laparoscopic regional gastrectomy combined with sentinel lymph node dissection in the treatment of early gastric cancer

A multicenter prospective clinical study of endoscopic laparoscopic regional gastrectomy combined with sentinel lymph node dissection in the treatment of early gastric cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090687
Enrollment
Unknown
Registered
2024-10-11
Start date
2024-10-12
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

New operation group:Endoscopic-laparoscopic regional gastric resection + sentinel lymph node navigation surgery
Standard radical gastrectomy group:Laparoscopic radical gastrectomy

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Age: 18-80 years old (including 18 and 80 years old); ? Gender is not limited; ? Early gastric cancer after ESD relative enlargement indication or ESD non-curable resection; ? endoscopic lift sign is positive; ? Physical strength score: ECOG=2 points, can tolerate standard radical gastrectomy; ? No history of gastrointestinal surgery, chemotherapy or radiotherapy; Liver, kidney, heart, lung, bone marrow function was normal (GPT4×109/L, PLT > 100×109/L); Able to understand and abide by the research protocol, agree and sign the informed consent.

Exclusion criteria

Exclusion criteria: ? Patients whose tracer staining range cannot be determined; ? The use of tracers or gastroscopy contraindications; (3) Failure to receive ESD treatment or ESD failure; (4) Coagulopathy, cardiopulmonary insufficiency and other surgical contraindication, or uncontrolled epilepsy, central nervous system disease or mental disorder history, or organ transplantation requires immunosuppressive treatment; (5) Pregnancy, lactation, pregnancy may not take effective contraceptive measures and prepare to conceive; ? Patients with other systemic malignancies; Or the intraoperative evidence was metastatic gastric cancer or non-gastric cancer; ? Participate in other clinical trials.

Design outcomes

Primary

MeasureTime frame
5-year recurrence rate;

Countries

China

Contacts

Public ContactShu tian Zhang

Beijing Friendship Hospital, Capital Medical University

zhangshutian@ccmu.edu.cn+86 183 1100 2896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026